This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://localhost/temp/predkladatel/
n8http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n12http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11110%2F14%3A10288209%21RIV15-MSM-11110___/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11110%2F14%3A10288209%21RIV15-MSM-11110___
rdf:type
n11:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1007/s40264-014-0238-8
dcterms:description
Incretin-based therapies either increase endogenous levels of glucagon-like peptide-1 by prolonging its half-life (DPP-4 inhibitors) or directly stimulate its receptor (glucagon-like peptide-1 analogues; GLP-1 RA). They are currently widely used for the treatment of patients with type 2 diabetes mellitus owing to good antidiabetic efficacy, low risk of hypoglycemia, and relatively few other side effects. They also offer potential additional benefits such as weight neutrality or weight loss, positive effects on blood pressure and lipid levels, and potential cardio- and neuroprotectivity. Some experimental and clinical studies have raised concerns with respect to potential cardiovascular and pancreatic side effects of these therapies such as increased risk of heart failure with DPP-4 inhibitors as well as acute pancreatitis and pancreatic cancer with both classes. The available data are at present not robust enough to enable firm conclusions regarding these potential associations. Nevertheless, some recent data suggest a possibility of slightly increased risk of acute pancreatitis with GLP-1 RAs while they do not indicate increased risk of pancreatic cancer. Ongoing cardiovascular outcome trials will shed more light on the possible cardioprotective effects of incretin-based therapies as well as on the possible interconnection of DPP-4 inhibitors and heart failure. Incretin-based therapies either increase endogenous levels of glucagon-like peptide-1 by prolonging its half-life (DPP-4 inhibitors) or directly stimulate its receptor (glucagon-like peptide-1 analogues; GLP-1 RA). They are currently widely used for the treatment of patients with type 2 diabetes mellitus owing to good antidiabetic efficacy, low risk of hypoglycemia, and relatively few other side effects. They also offer potential additional benefits such as weight neutrality or weight loss, positive effects on blood pressure and lipid levels, and potential cardio- and neuroprotectivity. Some experimental and clinical studies have raised concerns with respect to potential cardiovascular and pancreatic side effects of these therapies such as increased risk of heart failure with DPP-4 inhibitors as well as acute pancreatitis and pancreatic cancer with both classes. The available data are at present not robust enough to enable firm conclusions regarding these potential associations. Nevertheless, some recent data suggest a possibility of slightly increased risk of acute pancreatitis with GLP-1 RAs while they do not indicate increased risk of pancreatic cancer. Ongoing cardiovascular outcome trials will shed more light on the possible cardioprotective effects of incretin-based therapies as well as on the possible interconnection of DPP-4 inhibitors and heart failure.
dcterms:title
Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects
skos:prefLabel
Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects
skos:notation
RIV/00216208:11110/14:10288209!RIV15-MSM-11110___
n3:aktivita
n19:P
n3:aktivity
P(7E12077)
n3:cisloPeriodika
12
n3:dodaniDat
n4:2015
n3:domaciTvurceVysledku
n5:6061982 n5:2410230 n5:9338535
n3:druhVysledku
n17:J
n3:duvernostUdaju
n7:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
4804
n3:idVysledku
RIV/00216208:11110/14:10288209
n3:jazykVysledku
n15:eng
n3:klicovaSlova
receptor agonists; metabolic syndrome; glucose-homeostasis; heart-failure; myocardial-infarction; glp-1 analog liraglutide; type-2 diabetes-mellitus; dipeptidyl peptidase-4 inhibitors; randomized clinical-trials; Glucagon-like peptide-1
n3:klicoveSlovo
n13:glp-1%20analog%20liraglutide n13:glucose-homeostasis n13:metabolic%20syndrome n13:Glucagon-like%20peptide-1 n13:randomized%20clinical-trials n13:dipeptidyl%20peptidase-4%20inhibitors n13:receptor%20agonists n13:type-2%20diabetes-mellitus n13:myocardial-infarction n13:heart-failure
n3:kodStatuVydavatele
NZ - Nový Zéland
n3:kontrolniKodProRIV
[EBF911A7EA0A]
n3:nazevZdroje
Drug Safety
n3:obor
n20:FB
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
3
n3:projekt
n8:7E12077
n3:rokUplatneniVysledku
n4:2014
n3:svazekPeriodika
37
n3:tvurceVysledku
Svačina, Štěpán Mráz, Miloš Haluzík, Martin
n3:wos
000345391800002
s:issn
0114-5916
s:numberOfPages
8
n12:doi
10.1007/s40264-014-0238-8
n16:organizacniJednotka
11110